Table 3.
Evaluation of the relationship between clinical parameters and CSI-A score in axSpA patients
| Variable | CSI-A | |
|---|---|---|
| r | p-value | |
| Age (yr)† | 0.083 | 0.374 |
| Disease duration (yr) | 0.021 | 0.820 |
| First symptom duration (yr) | 0.050 | 0.592 |
| Age of Inflammatory back pain onset† | –0.014 | 0.885 |
| VAS-pain score | 0.582 | <0.001* |
| Patient Global Assessment score | 0.608 | <0.001* |
| Physician Global Assessment score | 0.596 | <0.001* |
| BASDAI score | 0.720 | <0.001* |
| BASFI score | 0.593 | <0.001* |
| BASMI score | 0.072 | 0.440 |
| ASQoL score | 0.728 | <0.001* |
| ESR (mm/h) | 0.074 | 0.432 |
| CRP (mg/L) | 0.026 | 0.781 |
| ASDAS-CRP score† | 0.519 | <0.001* |
| MASES score | 0.434 | <0.001* |
axSpA: axial spondyloarthritis, CSI-A: Central Sensitization Inventory A, VAS: visual analogue scale, BASDAI: Bath Ankylosing Spondylitis Disease activity Index, BASFI: Bath Ankylosing Spondylitis Functional Index, BASMI: Bath Ankylosing Spondylitis Metrology Index, ASQoL: Ankylosing Spondylitis Quality of Life, ESR: erythrocyte sedimentation rate, CRP: C-reactive protein, ASDASCRP: Ankylosing Spondylitis Disease Activity Score-C-reactive protein, MASES: Maastricht Ankylosing Spondylitis Enthesitis Score. *Statistically significant (p<0.05). †Pearson’s correlation analysis, and unmarked indicates Spearman’s correlation analysis.